Clinical Trial Update: Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab [Phase 3]

View source ↗

Summary

Phase 3 trial of ligelizumab in chronic spontaneous urticaria was terminated. Results have been posted for patients who completed a prior ligelizumab study (as …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Ligelizumab (ligelizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: TERMINATED | Results posted: 2023-07-13